📋 Product Overview Table

🌐 Specification	🧾 Details
💊 Active Ingredient	Exemestane 25mg
🧪 Formulation	Aromatase Inhibitor Tablet (Steroidal)
🏭 Manufacturer	Natco Pharma Ltd.
💊 Dosage Form	Oral Tablet
📦 Packaging	30 Tablets in 1 Bottle
🩺 Indication	Postmenopausal hormone receptor-positive breast cancer
🇺🇸 US Brand Equivalent	Aromasin (by Pfizer)
⏱️ Delivery Time	6 to 15 days

🧬 Introduction – What is Xtane 25mg (Exemestane)?

Xtane is a powerful oral aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in postmenopausal women. Each tablet contains 25mg of Exemestane, the same active ingredient found in the globally prescribed brand Aromasin by Pfizer.

Manufactured by Natco Pharma Ltd, a leading Indian pharmaceutical company known for its oncology portfolio, Xtane is a steroidal aromatase inactivator, meaning it binds permanently to the aromatase enzyme and prevents the body from producing estrogen — a key hormone that promotes tumor growth in hormone-sensitive cancers.

Xtane is frequently used as second-line therapy after tamoxifen or other selective estrogen receptor modulators (SERMs), and it is also prescribed in cases where resistance to non-steroidal inhibitors like anastrozole or letrozole develops. Its clinical efficacy, combined with affordability and availability, makes Xtane a trusted choice for oncologists and patients worldwide.

🎥 Video Overview – Exemestane in Breast Cancer Therapy

📺 “Xtane (Exemestane) Explained – How It Helps in Breast Cancer Treatment”

🎬 Video Placeholder – Educational breakdown of Xtane’s mechanism and expected results.

Always consult your oncologist before starting Xtane. Regular monitoring is essential during therapy.

🔬 Pharmacological Profile

🧪 Property	📊 Details
Drug Class	Steroidal Aromatase Inactivator
Bioavailability	~42% (increased with fatty food intake)
Mechanism	Irreversible binding to aromatase enzyme
Elimination Half-Life	Approximately 24 hours
Metabolism	Hepatic (CYP3A4 pathway)
Excretion	Renal and fecal

💡 Dosing Guidelines

🗓️ Regimen	💊 Dose
Standard Adult Dose	25mg orally once daily after food
Duration	Typically 2–5 years, or as directed
Missed Dose	Skip and resume next dose; do not double

Xtane should be taken after a meal to enhance absorption.

⚠️ Side Effects & Safety

💥 Common Side Effects	❗ Serious Side Effects (Rare)
Hot flashes	Bone fractures, osteoporosis
Fatigue, joint pain	Depression, liver function impairment
Insomnia, nausea	Cardiovascular risks in susceptible patients

Contraindications: Pregnancy, breastfeeding, premenopausal women.

🧃 Storage Guidelines

Store at room temperature below 25°C
Keep bottle tightly closed and away from moisture
Keep out of reach of children

🌍 Global Availability & Import Advice

🌎 Country	📦 Import Status	📋 Prescription Required
🇺🇸 USA	Permitted via FDA personal import policy	Yes
🇬🇧 UK	Allowed under MHRA personal use rules	Yes
🇦🇺 Australia	Legal via TGA with valid prescription	Yes

🔗 Related Oncology Products (Internal Links)

💊 Product Name	🏭 Manufacturer	📖 Description
Letoval 2.5mg	Sun Pharma	Letrozole aromatase inhibitor for hormone-receptor-positive breast cancer
Tamoxifen 20mg	Kachhela Medex	SERM used in both pre and postmenopausal breast cancer treatment
Fempro 2.5mg	Cipla Ltd	Letrozole generic alternative with wide oncology use
Armotraz 1mg	Cipla Ltd	Anastrozole-based therapy used after surgery or radiation
Altraz 1mg	Alkem Laboratories	Generic Arimidex equivalent, non-steroidal AI

📚 References & External Resources

🩺 Oncologist’s Commentary – Dr. Sheetal Rao, MD (Medical Oncology)

“Xtane is a clinically significant steroidal AI that can be highly effective when patients show resistance to non-steroidal options. Its affordability and accessibility through Indian pharmaceutical channels provide an excellent alternative to Aromasin, especially for long-term cancer survivors.”

⚠️ Disclaimer

This article is intended for informational purposes only and should not replace medical advice. Always consult a licensed oncologist before starting or changing treatment with Xtane (Exemestane).